Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

232 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Computer-Aided Imaging Analysis of Probe-Based Confocal Laser Endomicroscopy With Molecular Labeling and Gene Expression Identifies Markers of Response to Biological Therapy in IBD Patients: The Endo-Omics Study.
Iacucci M, Jeffery L, Acharjee A, Grisan E, Buda A, Nardone OM, Smith SCL, Labarile N, Zardo D, Ungar B, Hunter S, Mao R, Cannatelli R, Shivaji UN, Parigi TL, Reynolds GM, Gkoutos GV, Ghosh S. Iacucci M, et al. Among authors: ungar b. Inflamm Bowel Dis. 2023 Sep 1;29(9):1409-1420. doi: 10.1093/ibd/izac233. Inflamm Bowel Dis. 2023. PMID: 36378498 Free PMC article.
Propagation of EBV-driven Lymphomatous Transformation of Peripheral Blood B Cells by Immunomodulators and Biologics Used in the Treatment of Inflammatory Bowel Disease.
Levhar N, Ungar B, Kopylov U, Fudim E, Yavzori M, Picard O, Amariglio N, Chowers Y, Shemer-Avni Y, Mao R, Chen MH, Ye Z, Eliakim R, Ben-Horin S. Levhar N, et al. Among authors: ungar b. Inflamm Bowel Dis. 2020 Aug 20;26(9):1330-1339. doi: 10.1093/ibd/izaa065. Inflamm Bowel Dis. 2020. PMID: 32322878
Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease-the Israeli Real-World Experience.
Kopylov U, Ron Y, Avni-Biron I, Koslowsky B, Waterman M, Daher S, Ungar B, Yanai H, Maharshak N, Ben-Bassat O, Lichtenstein L, Bar-Gil Shitrit A, Israeli E, Schwartz D, Zittan E, Eliakim R, Chowers Y, Ben-Horin S, Dotan I. Kopylov U, et al. Among authors: ungar b. Inflamm Bowel Dis. 2017 Mar;23(3):404-408. doi: 10.1097/MIB.0000000000001039. Inflamm Bowel Dis. 2017. PMID: 28178003
Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.
Ungar B, Kopylov U, Yavzori M, Fudim E, Picard O, Lahat A, Coscas D, Waterman M, Haj-Natour O, Orbach-Zingboim N, Mao R, Chen M, Chowers Y, Eliakim R, Ben-Horin S. Ungar B, et al. Clin Gastroenterol Hepatol. 2018 May;16(5):697-705.e7. doi: 10.1016/j.cgh.2017.11.050. Epub 2017 Dec 7. Clin Gastroenterol Hepatol. 2018. PMID: 29223444
Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study.
Kopylov U, Verstockt B, Biedermann L, Sebastian S, Pugliese D, Sonnenberg E, Steinhagen P, Arebi N, Ron Y, Kucharzik T, Roblin X, Ungar B, Shitrit AB, Ardizzone S, Molander P, Coletta M, Peyrin-Biroulet L, Bossuyt P, Avni-Biron I, Tsoukali E, Allocca M, Katsanos K, Raine T, Sipponen T, Fiorino G, Ben-Horin S, Eliakim R, Armuzzi A, Siegmund B, Baumgart DC, Kamperidis N, Maharshak N, Maaser C, Mantzaris G, Yanai H, Christodoulou DK, Dotan I, Ferrante M. Kopylov U, et al. Among authors: ungar b. Inflamm Bowel Dis. 2018 Oct 12;24(11):2442-2451. doi: 10.1093/ibd/izy155. Inflamm Bowel Dis. 2018. PMID: 29788318
Pharmacokinetics and Immune Reconstitution Following Discontinuation of Thiopurine Analogues: Implications for Drug Withdrawal Strategies.
Ben-Horin S, Van Assche G, Chowers Y, Fudim E, Ungar B, Picard O, Yavzori M, Kopylov U, Mao R, Chen MH, Peled Y, Gueta I, Eliakim R, Loebstein R, Markovits N. Ben-Horin S, et al. Among authors: ungar b. J Crohns Colitis. 2018 Nov 28;12(12):1410-1417. doi: 10.1093/ecco-jcc/jjy122. J Crohns Colitis. 2018. PMID: 30169593
I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease.
Peyrin-Biroulet L, Rahier JF, Kirchgesner J, Abitbol V, Shaji S, Armuzzi A, Karmiris K, Gisbert JP, Bossuyt P, Helwig U, Burisch J, Yanai H, Doherty GA, Magro F, Molnar T, Löwenberg M, Halfvarson J, Zagorowicz E, Rousseau H, Baumann C, Baert F, Beaugerie L; I-CARE Collaborator Group. Peyrin-Biroulet L, et al. Clin Gastroenterol Hepatol. 2023 Mar;21(3):771-788.e10. doi: 10.1016/j.cgh.2022.09.018. Epub 2022 Sep 22. Clin Gastroenterol Hepatol. 2023. PMID: 36152897 Free article.
232 results